Patents by Inventor Alan List

Alan List has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS
    Patent number: 9738933
    Abstract: Disclosed herein is a method of using erythroid expression levels of RNF41 as a predictive biomarker for responsiveness to lenalidomide (LEN) in patients with non-del(5q) MDS.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: August 22, 2017
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventor: Alan List
  • ICARIIN DERIVATIVES
    Publication number: 20170044127
    Abstract: Disclosed are derivatives of icariin. Disclosed are compounds having Formula I-VIII as defined herein. Methods of using these compounds for the treatment of cancer and inflammation are also disclosed.
    Type: Application
    Filed: January 23, 2015
    Publication date: February 16, 2017
    Inventors: Sheng Wei, Alan List, Nicholas Lawrence
  • RNF41 AS A BIOMARKER PREDICTING RESPONSE TO LENALIDOMIDE IN NON-DEL(5Q) MDS
    Publication number: 20150344953
    Abstract: Disclosed herein is a method of using erythroid expression levels of RNF41 as a predictive biomarker for responsiveness to lenalidomide (LEN) in patients with non-del(5q) MDS.
    Type: Application
    Filed: December 5, 2013
    Publication date: December 3, 2015
    Inventor: Alan List
  • TARGETED SENSITIZATION OF NON-DEL(5q) MALIGNANT CELLS
    Publication number: 20150343078
    Abstract: Disclosed are molecules for treating non-del(5q) MDS that mimic allelic deficiency in del5q MDS to sensitize the malignant clones of patient without del(5q). The disclosed molecule contains an inhibitor of Cdc25C, an inhibitor of PP2Ac?, or a combination thereof, and a toll like receptor-9 (TLR9) targeting ligand. The molecule can also contain lenalidomide, or an analogue or derivative thereof. Also disclosed is a composition comprising the disclosed molecule in a pharmaceutically acceptable carrier. Also disclosed is a method for treating non-del(5q) meylodysplastic syndrome (MDS) in a subject by administering to the subject a therapeutically effective amount of the disclosed pharmaceutical composition.
    Type: Application
    Filed: January 21, 2014
    Publication date: December 3, 2015
    Inventors: Alan List, Sheng Wei
  • Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
    Publication number: 20060128716
    Abstract: The present invention relates to a method of treating myelodysplastic syndromes comprising administering a therapeutically effective amount of a 4-pyridylmethyl-phthalazine derivative to a warm-blooded animal in need thereof.
    Type: Application
    Filed: September 23, 2003
    Publication date: June 15, 2006
    Inventors: Margaret Dugan, Alan List